P15.01 AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer

Abstract

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by initial response to chemotherapy and radiotherapy followed by relapse and rapid progression. Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is highly expressed on the surface of most SCLC tumors; DLL3 expression is minimal and mainly cytoplasmic in normal tissues. AMG 757 is an investigational HLE BiTE immune therapy designed to redirect cytotoxic T cells to SCLC cells by binding to DLL3 on tumor cells and CD3 on T cells, resulting in T-cell activation and expansion and T cell–dependent killing of tumor cells.